A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients with Platinum Resistant Ovarian Cancer
This clinical trial is assessing two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine, and durvalumab (MEDI4736) , which is an antibody drug that helps "unblock" parts of the immune system. The aim of this study is to find out whether these drugs, when given together, are safe and effective for treating platinum-resistant ovarian cancer. TPIV200 is an injection given intradermally (into the skin) and durvalumab is given intravenously (into a vein).
This study is for patients who:
- Have recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Have a resolution of the adverse effects of prior therapies before entering the study, with the last dose of therapy given at least 3 weeks before the first dose of the study drugs.
- Are age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Jason Konner at 646-888-4219.